USF TrialNet Clinical Center
USF TrialNet 临床中心
基本信息
- 批准号:8776564
- 负责人:
- 金额:$ 41.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdultCaringCell physiologyChildhoodClinicalClinical ResearchCommitDevelopmentDiabetes MellitusDiagnosisEligibility DeterminationEnrollmentFloridaFundingIndianaIndividualInsulinInsulin-Dependent Diabetes MellitusInterventionIntervention TrialLeadershipMissionOnset of illnessParticipantPathway interactionsPatientsPersonsPopulations at RiskPreventionProductionProviderResidual stateRiskRoleScientific EvaluationSecureTestingUniversitiesVotingWorkdesigneffective interventionexperiencehigh riskinnovationinsightmembernovel strategiespreventpublic health relevanceresearch facilityscreening
项目摘要
DESCRIPTION (provided by applicant): The objectives of Type 1 Diabetes TrialNet are to delay or prevent the development of T1D in persons at risk and to preserve ¿-cell function in those with T1D possessing residual ¿-cell function through a highly collaborative network designed to identify individuals at-risk for T1D and to determine their eligibility for- and enrollment into prevention trials and to perform "new- onset" intervention trials. The USF Diabetes Center has been a very productive Affiliate of the University of Florida and has engaged with the TrialNet Coordinating Center at the University of South Florida to develop novel approaches to increase TrialNet enrollment. The Center is comprised of a committed multi-disciplinary team operating from a state-of-the-art, dedicated clinical and clinical research
facility serving greater than 1,400 pediatric and adult patients with T1D. In addition, it has established a regional collaborative network of diabetes care providers with access to thousands of additional existing- and new-onset T1D patients. The PI's experience, including roles as the Indiana University DPT-1 Regional Recruitment Center Director, former Director of the Indiana University TrialNet Clinical Center, and as Chair of the Pathway to Prevention Study, and his successful engagement of T1D stakeholders, have enabled him to make vital contributions to TrialNet and has provided him with valuable insight into TrialNet's current limitations and opportunities for expansion. Funding of the USF TrialNet Clinical Center will greatly enhance his involvement in TrialNet as a voting member of the Steering Committee, potential member of the Clinical Leadership Committee, and collaborator of the Clinical Network Hub. Funding will also permit marked expansion of TrialNet recruitment in the West Central Florida region and gain access to hereto for untapped at-risk populations. The USF Diabetes Center's commitment to pursue clinical studies seeking to ameliorate the development of T1D is evidenced by the marked increase in our TrialNet screening activity, the number of our diabetes clinical trails, and our work with the TrialNet TNCC to develop innovative screening initiatives. Our participation as a TrialNet Clinical Center will permit us to markedly expand our current collaborative efforts on behalf of TrialNet.
描述(由申请人提供): 1 型糖尿病 TrialNet 的目标是延迟或预防高危人群患 T1D 并保持 ¿ -T1D 患者的细胞功能有残留 ¿ - 通过高度协作的网络发挥细胞功能,该网络旨在识别有 T1D 风险的个体,并确定他们是否有资格参加预防试验并进行“新发”干预试验。南佛罗里达大学糖尿病中心一直是一个非常富有成效的附属机构。佛罗里达大学的 TrialNet 协调中心与南佛罗里达大学的 TrialNet 协调中心合作,开发增加 TrialNet 注册人数的新颖方法。该中心由一支致力于运营的最先进的多学科团队组成。专门的临床和临床研究
该机构为超过 1,400 名儿童和成人 T1D 患者提供服务。此外,它还建立了一个糖尿病护理提供者的区域合作网络,可以接触到数千名其他现有和新发 T1D 患者的经验,包括作为印第安纳州的角色。大学 DPT-1 区域招聘中心主任、印第安纳大学 TrialNet 临床中心前主任、预防途径研究主席,以及他与 T1D 利益相关者的成功接触,使他能够为 TrialNet 做出重要贡献并为他提供了有关 TrialNet 当前局限性和扩展机会的宝贵见解。 USF TrialNet 临床中心的资助将极大地增强他作为指导委员会投票成员、临床领导委员会潜在成员和合作者对 TrialNet 的参与程度。临床网络中心的资金还将允许在佛罗里达州中西部地区显着扩大 TrialNet 的招募范围,并为尚未开发的高危人群提供机会,以致力于开展旨在改善糖尿病发展的临床研究。我们的 TrialNet 筛查活动、糖尿病临床试验数量的显着增加以及我们与 TrialNet TNCC 合作开发创新筛查举措都证明了我们作为 TrialNet 临床中心的参与将使我们能够显着扩大我们当前的合作。代表 TrialNet 所做的努力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HENRY RODRIGUEZ其他文献
HENRY RODRIGUEZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HENRY RODRIGUEZ', 18)}}的其他基金
TYPE 1 DIABETES TRIALNET PROTOCOL TN-05 / EFFECTS OF RITUXIMAB ON THE PROGRESS
1 型糖尿病试验方案 TN-05 / Rituximab 对进展的影响
- 批准号:
7717573 - 财政年份:2007
- 资助金额:
$ 41.13万 - 项目类别:
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL - DACLIZUMAB CLINICAL TRIAL
1 型糖尿病新发霉酚酸酯 - 达利珠单抗临床试验
- 批准号:
7717510 - 财政年份:2007
- 资助金额:
$ 41.13万 - 项目类别:
NATURAL HISTORY OF THE DEVELOPMENT OF TYPE 1 DIABETES
1 型糖尿病发展的自然史
- 批准号:
7717502 - 财政年份:2007
- 资助金额:
$ 41.13万 - 项目类别:
TYPE 1 DIABETES TRIALNET PROTOCOL TN-05 / EFFECTS OF RITUXIMAB ON THE PROGRESS
1 型糖尿病试验方案 TN-05 / Rituximab(利妥昔单抗)对进展的影响
- 批准号:
7606476 - 财政年份:2006
- 资助金额:
$ 41.13万 - 项目类别:
NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL - DACLIZUMAB CLINICAL TRIAL
1 型糖尿病新发霉酚酸酯 - 达利珠单抗临床试验
- 批准号:
7606413 - 财政年份:2006
- 资助金额:
$ 41.13万 - 项目类别:
NATURAL HISTORY OF THE DEVELOPMENT OF TYPE 1 DIABETES
1 型糖尿病发展的自然史
- 批准号:
7606405 - 财政年份:2006
- 资助金额:
$ 41.13万 - 项目类别:
NEW ONSET OF TYPE 1 DIABETES MYCOPHENLATE MOFETIL - DACLIZUMAB CLINICAL TRIAL
1 型糖尿病新发霉酚酸酯 - 达利珠单抗临床试验
- 批准号:
7379108 - 财政年份:2005
- 资助金额:
$ 41.13万 - 项目类别:
NATURAL HISTORY OF THE DEVELOPMENT OF TYPE 1 DIABETES
1 型糖尿病发展的自然史
- 批准号:
7379098 - 财政年份:2005
- 资助金额:
$ 41.13万 - 项目类别:
相似国自然基金
指向提议者的共情关怀对第三方惩罚行为的影响:心理、脑与计算机制
- 批准号:32371102
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
关怀效应与守门效应:员工-AI算法协作、任务情境与算法透明度对用户反应的影响
- 批准号:72372071
- 批准年份:2023
- 资助金额:42 万元
- 项目类别:面上项目
生命权视角下癌症晚期患者临终意愿依从性指标评估体系及管理模型构建
- 批准号:71904056
- 批准年份:2019
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
癌症患儿的康复景观与健康关怀实践:中美比较视角
- 批准号:41861029
- 批准年份:2018
- 资助金额:38.0 万元
- 项目类别:地区科学基金项目
晚期肿瘤患者“预立医疗照护计划”干预模式的构建及其实证研究
- 批准号:71663064
- 批准年份:2016
- 资助金额:30.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Investigating HDAC3 phosphorylation as an epigenetic regulator of memory formation in the adult and aging brain
研究 HDAC3 磷酸化作为成人和衰老大脑记忆形成的表观遗传调节剂
- 批准号:
10752404 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Analysis of Type 1 Diabetes Polygenic Scores in Atypical Forms of Diabetes
非典型糖尿病 1 型糖尿病多基因评分分析
- 批准号:
10750644 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Individualized Nutrition to Help Asthmatics Improve Lung Function and Energetics (INHALE)
个性化营养帮助哮喘患者改善肺功能和能量(INHALE)
- 批准号:
10724851 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Chromatin-based encoding of sex differentiation of neurons
基于染色质的神经元性别分化编码
- 批准号:
10603287 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Genetic Variants of Immune Dysregulation and Thrombotic Microangiopathy in Severe Pediatric Sepsis Induced Organ Dysfunction
严重小儿脓毒症引起的器官功能障碍中免疫失调和血栓性微血管病的遗传变异
- 批准号:
10571065 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别: